CN115697967A - 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用 - Google Patents

磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用 Download PDF

Info

Publication number
CN115697967A
CN115697967A CN202180037849.4A CN202180037849A CN115697967A CN 115697967 A CN115697967 A CN 115697967A CN 202180037849 A CN202180037849 A CN 202180037849A CN 115697967 A CN115697967 A CN 115697967A
Authority
CN
China
Prior art keywords
group
pharmaceutically acceptable
acceptable salt
groups
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037849.4A
Other languages
English (en)
Inventor
许建烟
高建红
章瑛
贺峰
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN115697967A publication Critical patent/CN115697967A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

提供一种磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用。具体而言，提供了一种具有式(D)所示结构的磺酰苯甲酰胺类衍生物及其偶联物，其制备方法，含有其的药物组合物，及其通过受体调节在制备治疗癌症的药物中的用途。其中通式(D)中的各取代基与说明书中的定义相同。

Description

PCT国内申请，说明书已公开。

Claims (35)

  1. PCT国内申请，权利要求书已公开。
CN202180037849.4A 2020-07-10 2021-07-09 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用 Pending CN115697967A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020106631258 2020-07-10
CN202010663125 2020-07-10
PCT/CN2021/105436 WO2022007940A1 (zh) 2020-07-10 2021-07-09 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用

Publications (1)

Publication Number Publication Date
CN115697967A true CN115697967A (zh) 2023-02-03

Family

ID=79552813

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037849.4A Pending CN115697967A (zh) 2020-07-10 2021-07-09 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用

Country Status (11)

Country Link
US (1) US20230250077A1 (zh)
EP (1) EP4180422A4 (zh)
JP (1) JP2023533735A (zh)
KR (1) KR20230038231A (zh)
CN (1) CN115697967A (zh)
AU (1) AU2021306781A1 (zh)
BR (1) BR112023000320A2 (zh)
CA (1) CA3184959A1 (zh)
MX (1) MX2023000346A (zh)
TW (1) TW202214565A (zh)
WO (1) WO2022007940A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2012017251A1 (en) * 2010-08-06 2012-02-09 Astrazeneca Ab N-acylsulfonamide apoptosis promoters
CN110312531A (zh) * 2017-02-22 2019-10-08 阿斯利康(瑞典)有限公司 治疗性树枝状体
CN110483501A (zh) * 2016-08-05 2019-11-22 密歇根大学董事会 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
US20200216442A1 (en) * 2017-06-26 2020-07-09 Shenzhen Targetrx, Inc. Benzenesulfonylbenazamide compound for inhibiting bcl-2 protein and composition and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US7223879B2 (en) 1998-07-10 2007-05-29 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
WO2012017251A1 (en) * 2010-08-06 2012-02-09 Astrazeneca Ab N-acylsulfonamide apoptosis promoters
CN110483501A (zh) * 2016-08-05 2019-11-22 密歇根大学董事会 作为bcl-2抑制剂的n-(苯基磺酰基)苯甲酰胺及相关化合物
CN110312531A (zh) * 2017-02-22 2019-10-08 阿斯利康(瑞典)有限公司 治疗性树枝状体
US20200216442A1 (en) * 2017-06-26 2020-07-09 Shenzhen Targetrx, Inc. Benzenesulfonylbenazamide compound for inhibiting bcl-2 protein and composition and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
郭翠翠 等: "新型邻苯磺酰氨基苯甲酰胺类化合物的合成与抗肿瘤活性", 《天津医科大学学报》, vol. 19, no. 4, pages 275 - 278 *

Also Published As

Publication number Publication date
AU2021306781A1 (en) 2023-03-02
TW202214565A (zh) 2022-04-16
JP2023533735A (ja) 2023-08-04
CA3184959A1 (en) 2022-01-13
EP4180422A1 (en) 2023-05-17
US20230250077A1 (en) 2023-08-10
KR20230038231A (ko) 2023-03-17
EP4180422A4 (en) 2024-01-24
MX2023000346A (es) 2023-02-13
BR112023000320A2 (pt) 2023-01-31
WO2022007940A1 (zh) 2022-01-13

Similar Documents

Publication Publication Date Title
JP6581630B2 (ja) 新規ベンゾジアゼピン誘導体
CN109803972B (zh) 1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
TWI740833B (zh) 半胱胺酸工程改造抗體之結合物
CN103896942A (zh) 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
HUE030846T2 (en) Conjugates of CC-1065 analogues and bifunctional linkers
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
CN110944990A (zh) Tlr7/8拮抗剂及其用途
JP6782250B2 (ja) Ｃｔｉファーマコフォアを含有する二官能性細胞毒性剤
CN112888460A (zh) Lrkk2的野生型及突变型的降解剂
JP2023508097A (ja) タンパク質分解剤化合物の製造方法及び使用
JP2018538292A (ja) 癌療法のためのモノマレイミド官能化白金化合物
CN113801111A (zh) 联苯类衍生物抑制剂及其制备方法和应用
CN113825757A (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
TW202106693A (zh) 吲哚類大環衍生物、其製備方法及其在醫藥上的應用
TW202214594A (zh) 含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用
JP7395723B2 (ja) 複素環式誘導体、医薬組成物および癌の処置または寛解におけるそれらの使用
US20210046082A1 (en) Crystalline forms of quinoline analogs and salts thereof, compositions, and their methods for use
TW202144369A (zh) 海鞘素類衍生物及其製備方法與醫藥用途
CN115697967A (zh) 磺酰苯甲酰胺类衍生物及其偶联物、其制备方法及其应用
WO2022148358A1 (zh) 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
TW202322819A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
TW202325298A (zh) 含氮的四環化合物、其製備方法及其在醫藥上的應用
CN114181277A (zh) 一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
CN114641314A (zh) 慢性肾脏病的治疗或预防方法
CN111187277B (zh) 噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088908

Country of ref document: HK